Objective To assess racial/ethnic differences in the use of biologic disease‐modifying
antirheumatic drugs (DMARDs) among California Medicaid (Medi‐Cal) rheumatoid arthritis …

Background The aim of this study was to explore the impact of sex and disease classification
on outcomes in axial spondyloarthritis (axSpA) patients, including both radiographic (r-) …

Objective: assessing health-related quality of life (HRQL) in patients with rheumatoid arthritis
(RA), before and after treatment with biological therapy. Methods: a longitudinal study …

Objectives Our goal was to determine the annual direct medical and nonmedical costs for
the care of patients with rheumatoid arthritis (RA) using data from a large cohort database in …

Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis
(RA). Here we present data from the completed Phase 3 randomised controlled trial (RCT) …

Immune-mediated inflammatory diseases (IMIDs) are chronic conditions that create a
significant disease burden on millions of patients while adding a major financial burden to …

Objective Randomised controlled trials (RCTs) have shown tocilizumab (TCZ) administered
intravenously or subcutaneously with conventional synthetic disease-modifying …

Background Infliximab (IFX) infusions require repeated hospitalizations. The median
duration of each hospitalization stay, including time for infusion and the cost for the health …

Objectives To establish if using intensive treatment to reduce synovitis and attain remission
in active rheumatoid arthritis (RA) improves all aspects of health-related quality of life …

Objective Two randomised controlled trials, AMBITION (NCT00109408) and ADACTA
(NCT01119859), showed tocilizumab (TCZ) monotherapy superior to methotrexate (MTX) …